tiprankstipranks
Shanghai Pharmaceuticals Holding Co Ltd Class H (DE:S1R)
FRANKFURT:S1R
Germany Market

Shanghai Pharmaceuticals Holding Co (S1R) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

S1R Analyst Ratings

Currently, no data available
Based on NaN analysts giving stock ratings to
Shanghai
Pharmaceuticals Holding Co
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

S1R Stock 12 Month Forecast

There Are No Analyst Ratings for DE:S1R In The Last 3 Months.
Highest Price TargetAverage Price TargetLowest Price Target
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

S1R Financial Forecast

S1R Earnings Forecast

Next quarter’s earnings estimate for S1R is €0.07 with a range of €0.06 to €0.09. The previous quarter’s EPS was €0.05. S1R beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year S1R has Performed in-line its overall industry.
Next quarter’s earnings estimate for S1R is €0.07 with a range of €0.06 to €0.09. The previous quarter’s EPS was €0.05. S1R beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year S1R has Performed in-line its overall industry.

S1R Sales Forecast

Next quarter’s sales forecast for S1R is €9.79B with a range of €9.79B to €9.79B. The previous quarter’s sales results were €9.47B. S1R beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year S1R has Performed in-line its overall industry.
Next quarter’s sales forecast for S1R is €9.79B with a range of €9.79B to €9.79B. The previous quarter’s sales results were €9.47B. S1R beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year S1R has Performed in-line its overall industry.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi Analyst forecast on DE:S1R
Unknown Analyst
Citi
Not Ranked
Citi
€1.51
Buy
17.20%
Upside
Reiterated
04/13/26
Shanghai Pharmaceuticals Holding Co (SHPMF) Receives a Buy from Citi
HSBC Analyst forecast on DE:S1R
Unknown Analyst
HSBC
Not Ranked
HSBC
€1.36€1.32
Sell
2.44%
Upside
Reiterated
11/10/25
HSBC Remains a Sell on Shanghai Pharmaceuticals Holding Co (SHPMF)
CICC Analyst forecast on DE:S1R
Unknown Analyst
CICC
Not Ranked
CICC
€1.65
Buy
27.61%
Upside
Reiterated
11/01/25
UBS Analyst forecast on DE:S1R
Unknown Analyst
UBS
Not Ranked
UBS
€1.68
Buy
30.22%
Upside
Reiterated
10/31/25
Bank of America Securities Analyst forecast on DE:S1R
Unknown Analyst
Bank of America Securities
Not Ranked
Bank of America Securities
€1.6
Buy
24.14%
Upside
Reiterated
08/29/25
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi Analyst forecast on DE:S1R
Unknown Analyst
Citi
Not Ranked
Citi
€1.51
Buy
17.20%
Upside
Reiterated
04/13/26
Shanghai Pharmaceuticals Holding Co (SHPMF) Receives a Buy from Citi
HSBC Analyst forecast on DE:S1R
Unknown Analyst
HSBC
Not Ranked
HSBC
€1.36€1.32
Sell
2.44%
Upside
Reiterated
11/10/25
HSBC Remains a Sell on Shanghai Pharmaceuticals Holding Co (SHPMF)
CICC Analyst forecast on DE:S1R
Unknown Analyst
CICC
Not Ranked
CICC
€1.65
Buy
27.61%
Upside
Reiterated
11/01/25
UBS Analyst forecast on DE:S1R
Unknown Analyst
UBS
Not Ranked
UBS
€1.68
Buy
30.22%
Upside
Reiterated
10/31/25
Bank of America Securities Analyst forecast on DE:S1R
Unknown Analyst
Bank of America Securities
Not Ranked
Bank of America Securities
€1.6
Buy
24.14%
Upside
Reiterated
08/29/25
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ENOVEnovis
GKOSGlaukos
IMUXImmunic
AVTXAvalo Therapeutics
TARAProtara Therapeutics
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Shanghai Pharmaceuticals Holding Co

3 Months
Success Rate
0/1 ratings generated profit
0%
Average Return
-4.20%
Copying xAi Medical - Distribution's trades and holding each position for 3 Months would result in 0.00% of your transactions generating a profit, with an average return of -4.20% per trade.
1 Year
Success Rate
0/1 ratings generated profit
0%
Average Return
-1.30%
Copying xAi Medical - Distribution's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -1.30% per trade.
2 Years
Success Rate
0/1 ratings generated profit
0%
Average Return
-1.30%
Copying xAi Medical - Distribution's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -1.30% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

S1R Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
0
0
0
0
0
Buy
0
1
1
1
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
0
1
1
1
0
In the current month, S1R has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. S1R average Analyst price target in the past 3 months is .
Each month's total comprises the sum of three months' worth of ratings.

S1R Stock Forecast FAQ

What is DE:S1R’s average 12-month price target, according to analysts?
Currently, no data Available
What is DE:S1R’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for DE:S1R, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is Shanghai Pharmaceuticals Holding Co Ltd Class H a Buy, Sell or Hold?
      Currently, no data Available
      What is Shanghai Pharmaceuticals Holding Co Ltd Class H’s share price target?
      Currently, no data Available
      What do analysts say about Shanghai Pharmaceuticals Holding Co Ltd Class H?
      Not enough analysts have published a price target to provide an average price target.
      How can I buy shares of Shanghai Pharmaceuticals Holding Co Ltd Class H?
      To buy shares of DE:S1R, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.